H2O Plus lapped up by investors
This article was originally published in The Rose Sheet
Goldman Sachs Urban Investment Group and private equity firm Cordova, Smart & Williams announce acquisition of prestige natural skin-care maker H2O Plus from brand founder Cindy Melk May 29. Investment firms will enjoy joint ownership of the company; Melk will be retained as H2O's chief creative officer. "H2O Plus presented a unique opportunity to invest in a well-positioned, fast-growing brand-name company in the natural and organic personal-care products sector," says Michael Smart, managing partner at CSW. "We believe that aligning our capital and resources with H2O Plus' talented management team will position the company for future growth on a global basis." H2O was founded in 1989; it currently offers about 160 spa, skin-care and bath products in 18 countries, according to release. Brand's international distribution has grown 200% in past two years, and Goldman Sachs and CSW see significant further growth potential in Asia, Europe and Latin America...
You may also be interested in...
NIVEA: Beiersdorf skin-care brand is new multi-year title sponsor for AVP professional beach volleyball tour kicking off April 16 in Fort Lauderdale, Fla., firm announces March 31. All tour events will feature the iconic NIVEA blue color, transforming tournament sites into a "sea of blue," according to the release. NIVEA plans to market its new Happy Sensation body lotion and Touch of Happiness body wash in conjunction with tour events through "advertising, on-site signage, sampling activations, retail activities, PR, contests and online [promotions]," it says. "With its iconic character, its dedication to skin- and body-care worldwide, NIVEA fits perfectly with the health and vitality of our players," notes AVP Commissioner Mike Dodd
In a statement submitted to the Senate Finance Committee, Natural Products Association CEO Dan Fabricant suggests two ways of improving compliance with new dietary ingredient notification requirements at negligible expense to the US FDA.
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.